๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Enhancement or inhibition of tumor growth by interferon: Dependence on treatment protocol

โœ Scribed by Donna M. Murasko; Kerin Fresa; Raymond Mark


Publisher
John Wiley and Sons
Year
1983
Tongue
French
Weight
891 KB
Volume
32
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

โœฆ Synopsis


Abstract

MSC cells are tumor cells originally induced in BALB/c mice by Moloney sarcoma virus. In these studies we demonstrated that, although these tumor cells are sensitive in vitro both to lysis by NK or NKโ€like cells and to the growthโ€inhibitory effect of murine Lโ€cell interferon (IFN), the growth of the tumor in vivo could be either inhibited or enhanced by IFN. The outcome of in vivo IFN treatment was dependent on the timing and route of IFN administration relative to tumor challenge. IFN given systemically at the same time as tumor challenge resulted in enhancement of primary tumor formation, rate of tumor growth and subsequent progressive tumor growth. In contrast, IFN administered at the site of tumor inoculation on days 1โ€“3 after tumor challenge inhibited tumor formation and growth. Histopathology of tissue sections obtained from the site of tumor challenge confirmed these results. Similar studies performed in mice given 450 rads of Xโ€irradiation showed that IFN could still inhibit tumor growth when administered at the site of tumor inoculation on days 1โ€3 after tumor challenge. IFN administered simultaneously with tumor challenge, however, did not enhance tumor growth in irradiated mice. These results are consistent with the interpretation that 1) inhibition of MSCโ€induced tumor growth by IFN has a radioresistant component and 2) the enhancement of MSCโ€induced tumor formation by IFN is dependent on interaction with a radiosensitive population of cells, possibly lymphoid cells.


๐Ÿ“œ SIMILAR VOLUMES


Transforming growth factor-ฮฒ1 enhances t
โœ Garwin K. Sing; Jonathan R. Keller; Larry R. Ellingsworth; Francis W. Ruscetti ๐Ÿ“‚ Article ๐Ÿ“… 1989 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 439 KB

The effects of transforming growth factor-01 (TGF-01) on human hematopoiesis were evaluated in combination with two other regulatory cytokines, namely, recombinant human tumor necrosis factor-a! (TNF-a) and recombinant human interferon-a (rIFN-a). Combinations of TNF-a and TGF-01 resulted in a syner

Production of tumor growth-inhibiting pr
โœ Nobuhiko Miwa; Tetsuya Matsuno; Satoshi Mizuno ๐Ÿ“‚ Article ๐Ÿ“… 1987 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 667 KB

We previously reported that the mouse brain at the neonatal stage but not at the adult stage secreted a carcinostatic factor of 62,000 Da, termed NBCF, which inhibited clonal growth and DNA synthesis of malignant cells preferentially over those of normal cells. In the present study, NBCF production

CXCR4 peptide antagonist inhibits primar
โœ Saima Hassan; Marguerite Buchanan; Kaushar Jahan; Adriana Aguilar-Mahecha; Louis ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 527 KB

## Abstract CXCR4 is a chemokine receptor implicated in the homing of cancer cells to target metastatic organs, which overexpress its ligand, stromal cellโ€derived factor (SDF)โ€1. To determine the efficacy of targeting CXCR4 on primary tumor growth and metastasis, we used a peptide inhibitor of CXCR

Inhibition of interleukin 4-promoted CD2
โœ John Gordon; Anita Katira; Alistair J. Strain; Steven Gillis ๐Ÿ“‚ Article ๐Ÿ“… 1991 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 667 KB

Inhibition of interleukin Lt-promoted 0 2 3 production in human B lymphocytes by transforming growth factor-p, interferons or anti-CD19 antibody is ovemden on engaging m 4 0 \* Interleukin 4 (IL4) is an essential component in the sequence of events directing IgE synthesis in uncommitted B lymphocyte